Abbott Laboratories Redburn Upgrade Analysis: Volt PFA, Libre and Cologuard at 16x Forward Earnings — Why We See $115 Base-Case Value

Table of Contents

On October 2, 2026, Rothschild & Co Redburn upgraded Abbott Laboratories (NYSE: ABT) from Neutral to Buy and lifted its price target from $119 to $127. The timing is notable. Abbott shares now trade at $97.50, roughly 28% below their 52-week high of $135.37 and below both the 50-day moving average ($107.10) and the 200-day moving average ($98.68), according to MarketBeat data. A company that has raised its dividend for 54 consecutive years, sells the leading continuous glucose monitor by revenue, and just bought the maker of Cologuard is being priced at 16.07x next year’s consensus earnings.

The Abbott Redburn upgrade lands at a moment when sentiment across large-cap medtech is poor. Boston Scientific set a fresh 52-week low of $42.60 on October 2, Medtronic trades at 13.51x forward earnings, and Stryker at 16.47x. Abbott has been dragged down with the group, but its own 2026 has also been messy: a FreeStyle Libre 3 sensor recall, a guidance cut tied to the $23 billion Exact Sciences acquisition, a weak nutrition business, and a $670 million settlement of infant-formula litigation. The question for investors is whether those problems are now in the price.

We think mostly yes. Here are the three investment points behind that view.

1. The medical devices engine is accelerating, not slowing. Abbott’s Medical Devices segment grew 8.4% on a comparable basis in Q2 2026 to $5.85 billion, with Electrophysiology up 13.4% and Diabetes Care up 9.0%. Redburn expects the segment to grow 10.6% organically in fiscal 2026, driven by U.S. uptake of the Volt pulsed field ablation (PFA) system and the TactiFlex Duo catheter. Volt 2.0 entered limited U.S. release in May and moved to full market release in Q3.

2. Exact Sciences changes the diagnostics growth profile. The new Cancer Diagnostics line delivered $919 million in Q2 sales with 13.3% comparable growth, and management now describes the combined diagnostics portfolio as a 7%–8% grower once China volume-based procurement (VBP) pressure fades. That is a structural upgrade from a business that spent 2023–2025 shrinking its COVID-testing base.

3. The valuation already discounts the bad news. At $97.50, Abbott trades at 16.07x the consensus 2027 EPS of $6.07 and about 17.6x the midpoint of its raised 2026 adjusted EPS guidance ($5.45–$5.60). The dividend yield is roughly 2.6%. Even a modest re-rating to 19x forward earnings gets you to about $115.

This article walks through Abbott’s business model, the industry dynamics in CGM, cardiac ablation, and cancer screening, the durability of its competitive moats, five years of financials, a step-by-step valuation with bull/base/bear scenarios, the key risks, and an actionable entry and exit plan ahead of the October 21 third-quarter report.

—

1. Company Overview

Abbott Laboratories is a diversified healthcare company that generates revenue by selling physical products — sensors, catheters, implants, diagnostic instruments and test consumables, branded generic drugs, and nutrition products — to hospitals, laboratories, pharmacies, governments, and consumers in more than 160 countries. Unlike a pure pharmaceutical company, Abbott does not depend on a handful of patent-protected blockbusters. Its revenue is spread across four reportable segments, and a large portion comes from recurring consumables (glucose sensors, assay reagents, ablation catheters) that are bought over and over again.

The business model is simple to describe and hard to replicate: Abbott places an installed base (a diagnostic analyzer in a hospital lab, a mapping system in an electrophysiology lab, a Libre reader app on a patient’s phone) and then earns a recurring stream from the consumables that run on it.

Revenue breakdown by segment (Q2 2026)

Segment	Q2 2026 Sales	Share of Total	Comparable Growth
Medical Devices	$5,853M	46.5%	+8.4%
Diagnostics (incl. Cancer Diagnostics)	$3,092M	24.6%	+2.9%
Nutrition	$2,144M	17.0%	(3.6)%
Established Pharmaceuticals	$1,499M	11.9%	+8.7%
Total	$12,593M	100%	+4.8%

Source: Abbott Q2 2026 earnings release. Comparable growth includes prior- and current-year Exact Sciences sales.

Within Medical Devices, the sub-businesses tell the real story:

Device Business	Q2 2026 Sales	Comparable Growth
Diabetes Care (FreeStyle Libre)	$2,188M	+9.0%
Electrophysiology	$861M	+13.4%
Vascular	$803M	+5.1%
Rhythm Management	$743M	+9.5%
Structural Heart	$597M	+5.7%
Heart Failure	$401M	+8.7%
Neuromodulation	$260M	+1.2%

Diabetes Care alone is now a business running at more than $8.7 billion annualized (est., Q2 x4), with CGM sales exceeding $2 billion in the quarter, up 9.5%. Electrophysiology is approaching a $3.5 billion annualized run rate (est.).

Key customers and market position. Abbott’s customers range from national health systems and insurers (which decide CGM reimbursement) to hospital electrophysiology labs, reference laboratories, retail pharmacies, and the U.S. WIC infant-formula program. According to Mordor Intelligence, Abbott held 52.83% of global CGM revenue in 2025, versus 33.89% for Dexcom and 10.10% for Medtronic. In diagnostics, Abbott is a major core-laboratory and point-of-care supplier, and with Exact Sciences it now owns Cologuard, which the American Cancer Society reaffirmed (alongside Cologuard Plus) as a preferred colorectal cancer screening option during Q2.

Ownership and governance. Institutional investors own about 75.18% of Abbott’s shares, per MarketBeat. Robert Ford has served as CEO since 2020 and is also chairman. The board’s capital allocation has historically prioritized the dividend: Abbott raised its quarterly payout 6.8% to $0.63 in December 2025, its 54th consecutive annual increase, and has paid 408 consecutive quarterly dividends since 1924, according to the company. Abbott is a member of the S&P 500 Dividend Aristocrats index.

—

2. Industry Analysis: CGM, Cardiac Ablation and Cancer Screening

The Abbott Redburn upgrade is fundamentally a bet on three industries in which Abbott is positioned to grow faster than the broader medtech market. Each is at a different point in its cycle, and that mix is what makes the investment case more durable than any single product story.

2-1. Market Size & Growth Trajectory

Continuous glucose monitoring (CGM). Mordor Intelligence sizes the global CGM market at $15.77 billion in 2026, with North America at roughly $10.38 billion and Europe at roughly $3.57 billion. More important than the current size is the penetration gap. On the Q2 2026 call, management said 75–80 million people globally could realistically use CGM, while only about 15 million do today. That implies penetration of under 20% of the realistic addressable population. CGM is firmly in the acceleration phase: the technology is proven, costs have fallen sharply, and the gating factor is reimbursement, not demand.

Cardiac ablation / pulsed field ablation. Atrial fibrillation is a common and growing heart-rhythm disorder, and catheter ablation has been steadily displacing lifelong drug therapy. Pulsed field ablation, which uses electrical fields rather than heat or cold to create lesions, has transformed the field since 2024. Boston Scientific’s electrophysiology sales grew 24% to $905 million in Q1 2026, even as its CEO said it lost more share than expected to Medtronic, Johnson & Johnson and Abbott. The fact that Boston Scientific can grow 24% while losing share tells you the market itself is expanding rapidly. We place EP in the early acceleration phase — the technology shift to PFA is still under way, and new entrants are now competing on catheter design, mapping integration, and workflow.

Cancer screening and precision oncology diagnostics. Colorectal cancer screening remains under-penetrated in the U.S., and non-invasive stool-based testing has steadily taken share from colonoscopy as a first-line screen. Exact Sciences brings roughly $3 billion of incremental 2026 sales to Abbott (per TIKR), and Cologuard volume grew at a mid-teens rate in the first half of 2026. This market is in the growth-to-early-maturation phase: the stool-based test is established, while blood-based screening is an emerging competitive threat.

Abbott-wide growth targets. Management reiterated that 7% is the right long-term top-line growth target, with segment ranges of 2%–4% for nutrition, 7%–8% for diagnostics, 7%–9% for established pharma, and 8%–10% for medical devices. For 2026, guidance calls for 6.5%–7.5% comparable sales growth.

2-2. Structural Growth Drivers

Driver 1: CGM reimbursement expansion into Type 2 diabetes. The single most important lever for Libre is coverage, not technology. Management said Abbott is in active reimbursement discussions in about a dozen countries, and that expanding U.S. Medicare coverage to Type 2 patients who are not on intensive insulin therapy could open access for roughly 10 million beneficiaries — a “multi-billion dollar opportunity” in management’s words. This is a slow-moving but extremely large driver. Every time a payer adds a new class of patients, Abbott gains a cohort of users who replace sensors every 14–15 days for years. Abbott is already planning a fifth manufacturing facility, a $1 billion investment, which signals that management expects volume to keep compounding. In the short term, growth is somewhat restrained by the recall overhang and by competition in pharmacy channels; in the long term, the reimbursement curve is the dominant force. We also note that the Libre Duo — a dual glucose-ketone sensor — received a CE mark in Q2, with an international rollout planned and U.S. approval pending. Ketone sensing is clinically meaningful for patients on insulin pumps and for those at risk of diabetic ketoacidosis.

Driver 2: The PFA platform cycle in electrophysiology. Hospitals are re-equipping their EP labs for pulsed field ablation, and each procedure consumes single-use catheters. Abbott was late to U.S. PFA — the Volt system received FDA approval in December 2025 — but it has two advantages that matter. First, Volt integrates with Abbott’s EnSite 3D mapping system, which is already installed in a large base of EP labs; physicians can map and ablate within one workflow. Second, Abbott’s balloon-in-basket design allows procedures under conscious sedation rather than general anesthesia, which can improve lab throughput. Volt 2.0 entered limited U.S. release in May 2026 and moved to full release in Q3, while international Volt and TactiFlex Duo sales grew more than 20%. Management expects EP to outperform the market in the second half of 2026 and carry momentum into 2027, when the Amulet 360 left atrial appendage (LAA) occluder could launch (FDA submission completed; potential year-end approval). LAA closure is a natural companion procedure to ablation, giving Abbott a combined “AF franchise” offering. Short-term, the key metric is U.S. Volt adoption in Q3 and Q4; long-term, the question is what share Abbott can settle at in a market that will likely consolidate around three or four platforms.

Driver 3: Exact Sciences and the shift of diagnostics toward oncology. Abbott’s legacy diagnostics business spent three years digesting the collapse of COVID testing (COVID testing sales fell 60.2% in 2025 to $297 million) and the impact of China’s volume-based procurement program on core lab pricing. Exact Sciences resets that story. Cancer Diagnostics grew 13.3% in Q2, new-user demand for Cologuard has exceeded expectations, and repeat-screening funnels are expanding because patients who screen negative return every three years. Management expects second-half cancer diagnostics growth to exceed first-half growth as “care gap” programs with health plans ramp. Abbott’s global commercial reach can also accelerate Oncotype DX and other precision oncology tests outside the U.S. In the short term the deal is dilutive — it cut about $0.20 from 2026 adjusted EPS guidance — but over the long term it moves Abbott’s diagnostics mix toward a higher-growth, higher-margin profile. Redburn explicitly cited the improved “growth and margin profile” of diagnostics as part of its upgrade.

Driver 4: Mix-driven gross margin expansion. Abbott’s adjusted gross margin expanded 100 basis points year-over-year to 58.0% in Q2 2026, driven by favorable mix (including Exact Sciences) and margin initiatives. As devices and cancer diagnostics grow faster than nutrition, the company-wide margin should continue to drift higher — a quiet but powerful driver of EPS growth.

2-3. Competitive Landscape

Company	Market Cap	TTM Sales	Operating Margin	Forward P/E	Key Moat
Abbott (ABT)	$168.71B	$46.59B	16.44%	16.07x	Diversification, Libre scale, EnSite mapping base
Medtronic (MDT)	$110.49B	$37.54B	19.93%	13.51x	Broad cardiac/surgical portfolio, PulseSelect/Affera PFA
Stryker (SYK)	$105.65B	$25.84B	24.27%	16.47x	Orthopedics/robotics installed base
Boston Scientific (BSX)	$61.74B	$21.00B	21.80%	12.53x	Farapulse PFA franchise, Watchman LAA
Dexcom (DXCM)	$32.21B	$4.97B	22.92%	27.35x	CGM accuracy, pump integrations

Source: Finviz data as of October 2, 2026 close (TTM figures). Operating margins are GAAP and include acquisition amortization; Abbott’s figure is depressed by Exact Sciences deal costs.

Several observations stand out. First, large-cap medtech has de-rated as a group: Medtronic and Boston Scientific trade at roughly 12.5x–13.5x forward earnings, and Stryker at 16.5x. Abbott at 16.07x is not an outlier on the cheap side within this peer group, which is an important caveat to any “deep value” framing. Second, Abbott’s GAAP operating margin of 16.44% is the lowest in the table, but that is largely an artifact of acquisition-related amortization and integration costs; its adjusted gross margin of 58.0% tells a better story. Third, Dexcom, the pure-play CGM competitor, still commands 27.35x forward earnings — meaning the market values CGM growth highly when it is isolated, but applies a conglomerate discount when CGM sits inside Abbott.

Why Abbott is better positioned than peers. Against Boston Scientific, Abbott has the advantage of an incumbent mapping platform and is gaining share from a smaller PFA base, while BSX faces share loss from a very high base and also cut its 2026 sales growth guidance in April from 10.5%–11.5% to 7%–8.5%, citing Watchman, EP, and urology. Against Dexcom, Abbott has greater manufacturing scale and the leading revenue share in CGM, which supports lower-cost sensors and broader international reimbursement wins. Against Medtronic, Abbott has a cleaner growth algorithm and less exposure to slow-growing surgical categories. Its main disadvantage is the drag from nutrition and the complexity of being a four-segment conglomerate — which, as Redburn notes, could itself become a catalyst if management chooses to simplify.

—

3. Economic Moat Analysis

Moat Type 1: Switching Costs and Installed Base

Abbott’s strongest moat is the installed base that locks in recurring consumable revenue. In the EP lab, the EnSite mapping system is a capital investment around which physicians build workflows, training, and data. Once a lab is standardized on EnSite, adding Volt PFA catheters that integrate natively with that system is a lower-friction decision than introducing a second mapping platform. This is why Abbott can grow EP 13.4% even as a late entrant to U.S. PFA: it is selling into a base that already trusts its mapping infrastructure.

In core laboratory diagnostics, the switching-cost dynamic is even more pronounced. Hospital and reference labs validate assays on specific analyzers, integrate them with laboratory information systems, and train staff on them. Replacing an analyzer fleet is a multi-year project that labs undertake only at contract renewal. During those contract periods, Abbott sells the high-margin reagents that run on its machines.

In diabetes, switching costs are softer but real. Patients build habits around the Libre app, physicians review data through Abbott’s LibreView platform, and pharmacy benefit coverage often defaults to one brand. The FreeStyle Libre 3 recall in late 2025 (approximately 3 million sensors, with 860 serious injuries and seven deaths reported as of January 7, 2026) tested this moat. Yet CGM sales still grew 9.5% in Q2 2026 to more than $2 billion, which suggests the user base proved stickier than the headlines implied.

Moat Type 2: Cost Advantage Through Manufacturing Scale

CGM is a high-volume, precision-manufacturing business. Abbott held 52.83% of global CGM revenue in 2025 according to Mordor Intelligence, and that scale lowers its per-sensor cost. The Libre franchise was built from the beginning around affordability — Abbott priced sensors to win reimbursement in cost-conscious European health systems, and that discipline remains a competitive weapon as CGM expands into Type 2 patients, where payers are particularly price-sensitive. The planned fifth manufacturing facility ($1 billion investment) will further extend that scale.

Scale also matters in diagnostics, where Abbott’s global distribution network can carry Exact Sciences’ tests into international markets that Exact could not efficiently reach on its own, and in established pharmaceuticals, where Abbott’s branded generics business in emerging markets (growing 8.7% in Q2) depends on local manufacturing, distribution, and brand recognition among pharmacists.

Moat Type 3: Diversification as a Risk Moat

Diversification is often criticized as a “conglomerate discount,” and Redburn’s note implies some investors would prefer a simpler Abbott. But diversification also provides resilience. In 2026, Abbott absorbed a sensor recall, a nutrition slump, infant-formula litigation, and acquisition dilution — and still raised its full-year adjusted EPS guidance in July to $5.45–$5.60 while reaffirming 6.5%–7.5% comparable sales growth. Few single-franchise medtech companies could absorb four simultaneous negative events and still raise guidance. The dividend record — 54 consecutive annual increases — is the long-run evidence of this resilience.

Moat Durability Assessment

Will these moats hold for 5–10 years? We see three specific threats.

Threat 1: CGM commoditization. As CGM spreads into Type 2 and over-the-counter channels, price competition will intensify, and new entrants could pressure pricing. Counterargument: Abbott’s manufacturing scale (52.83% of 2025 global CGM revenue per Mordor Intelligence) positions it to compete if pricing pressure rises. The Libre Duo glucose-ketone sensor also offers feature differentiation.

Threat 2: PFA becomes a platform war Abbott does not win. Boston Scientific, Medtronic, and Johnson & Johnson are all investing heavily, and Abbott entered the U.S. later than its main rivals. Counterargument: Abbott does not need to “win” — EP grew 13.4% in Q2 with only limited U.S. Volt availability. A sustained mid-teens share of a fast-growing market is enough to support the thesis, and the EnSite installed base gives Abbott a durable entry point.

Threat 3: Blood-based colorectal cancer screening disrupts Cologuard. New blood tests could appeal to patients who resist stool sampling. Counterargument: Redburn expects Cologuard to remain the standard of care despite rising competition, Cologuard Plus was designed to reduce false positives versus the original test, and the American Cancer Society reaffirmed it as a preferred option. Abbott also says it aims for broad screening leadership, not just a defense of stool testing.

Overall, we rate Abbott’s moat as wide but uneven: strongest in diagnostics and EP mapping, solid in CGM, and weakest in nutrition.

—

투자 분석 이미지 — Photo by mostafa jamei on Unsplash

4. Financial Analysis

Five-year income statement (fiscal years ending December 31)

Metric	FY2021	FY2022	FY2023	FY2024	FY2025	TTM (Jun 2026)
Revenue	$43,075M	$43,653M	$40,109M	$41,950M	$44,328M	$46,585M
Gross Profit	$24,995M	$24,570M	$22,190M	$23,306M	$25,118M	$26,482M
Operating Income (GAAP)	$8,425M	$8,362M	$6,478M	$6,825M	$8,053M	~$7,660M (est.)
Net Income (GAAP)	$7,042M	$6,905M	$5,700M	$13,400M	$6,500M	$5,401M
Diluted EPS (GAAP)	$3.94	$3.91	$3.26	$7.64	$3.72	$3.09
Free Cash Flow	$8,648M	$7,804M	$5,059M	$6,351M	$7,395M	$7,824M

Source: StockAnalysis.com (gross profit for all periods, including TTM, on StockAnalysis’s basis); FY2021–FY2025 operating income from Abbott’s 10-K filings (GAAP). TTM operating income estimated from Finviz’s 16.44% operating margin on TTM sales of $46.59B; other TTM figures consistent with Finviz (Sales $46.59B, Income $5.41B).

The story behind each year.

– 2021–2022: The COVID testing peak. Revenue of $43–44 billion was inflated by billions of dollars of COVID-19 test sales (BinaxNOW and lab assays). Operating income was roughly $8.4 billion in both years.
– 2023: The COVID cliff. Revenue fell 8.1% to $40.1 billion as COVID testing collapsed, and operating income dropped to $6.5 billion. The underlying business kept growing, but reported numbers masked it.
– 2024: Base-business recovery. Revenue grew 4.6% to $41.95 billion. GAAP net income of $13.4 billion (EPS $7.64) was inflated by a large one-time, non-cash tax benefit and should not be used as a run-rate figure.
– 2025: Clean growth year. Revenue rose 5.7% to $44.3 billion (5.5% organic; 6.7% excluding COVID testing), and adjusted diluted EPS grew 10% to $5.15. GAAP EPS was $3.72. However, the stock fell after Q4 results as nutrition weakness and a revenue miss overshadowed EPS growth.
– TTM to June 2026: Acquisition noise. TTM revenue of $46.59 billion includes roughly one quarter of Exact Sciences sales. GAAP operating income fell to about $7.66 billion and GAAP EPS to $3.09 because of acquisition-related amortization, integration costs, and higher interest expense. That is why the trailing GAAP P/E of 31.51x looks expensive while the forward P/E of 16.07x looks reasonable — the gap reflects non-cash acquisition accounting plus forward earnings growth.

Key operating metrics.

– Q2 2026 total sales: $12.59 billion, +13.0% reported, +4.8% comparable — an acceleration from low-single-digit comparable growth in the prior two quarters.
– Q2 adjusted EPS: $1.31, above the $1.28 consensus estimate; GAAP EPS $0.53.
– Adjusted gross margin: 58.0%, up 100 basis points year-over-year.
– Q3 2026 adjusted EPS guidance: $1.38–$1.46.
– FY2026 adjusted EPS guidance: $5.45–$5.60 (raised from $5.38–$5.58 in April, which itself had been cut from the original $5.55–$5.80 to absorb roughly $0.20 of Exact Sciences dilution).

Nutrition: the drag that is starting to turn. Nutrition sales fell 7.7% in Q1 2026 on lower volumes in pediatric and adult products, and the U.S. pediatric business was hurt by the loss of a large WIC contract. In Q2 the decline narrowed to 3.6% on a comparable basis, sales rose $125 million sequentially, international pediatric nutrition returned to 6.5% growth, and U.S. Ensure retail consumption grew double digits versus 2025 exit rates. Management says about 80% of the expected second-half acceleration comes from nutrition, electrophysiology, core lab diagnostics, and cancer diagnostics.

Balance sheet highlights. The Exact Sciences deal transformed Abbott’s balance sheet. At December 31, 2025, Abbott had $8.94 billion of cash and short-term investments against $14.14 billion of debt — net debt of only $5.2 billion. After issuing $20 billion of senior notes in March 2026 to finance the deal, total debt reached $32.72 billion at June 30, 2026, against $5.60 billion of cash and short-term investments, for net debt of $27.12 billion. Goodwill and intangibles rose to $35.24 billion and $17.21 billion respectively. Shareholders’ equity was $51.76 billion. Finviz reports a debt-to-equity ratio of 0.64.

Net debt of $27.1 billion is about 3.5 years of TTM free cash flow ($7.82 billion). That is manageable for a company with Abbott’s cash-flow consistency, but it does mean that over the next two to three years, free cash flow beyond the dividend will likely go toward debt reduction rather than large buybacks.

Margin expansion story. Abbott is profitable, so the question is margin expansion. We see three levers: (1) mix shift toward devices and cancer diagnostics, which carry higher gross margins than nutrition; (2) Exact Sciences synergies as integration matures (management said integration is proceeding with no disruption); and (3) operating leverage as the nutrition business stabilizes. The Q2 adjusted gross margin gain of 100 basis points is early evidence. The FY2026 adjusted EPS midpoint of $5.525 implies about 7% growth over 2025’s $5.15 despite acquisition dilution, and consensus EPS for next year of $6.07 implies roughly 10% growth from that midpoint.

Dividend. The quarterly dividend of $0.63 ($2.52 annualized) equals a yield of about 2.6% at $97.50. With TTM free cash flow of $7.82 billion and roughly 1.73 billion shares outstanding, the dividend consumes approximately $4.4 billion (est.) per year — well covered.

—

5. Valuation

We value Abbott primarily on forward P/E, which is the standard method for a mature, profitable, diversified healthcare company, and cross-check with EV/Sales and dividend yield.

Step 1: Establish the earnings base.

– Current price: $97.50
– Shares outstanding: 1.73 billion; market cap $168.71 billion
– EPS (TTM, GAAP): $3.09 → trailing P/E 31.51x (distorted by acquisition amortization)
– Consensus EPS next year (2027): $6.07 → forward P/E = $97.50 ÷ $6.07 = 16.07x
– FY2026 adjusted EPS guidance midpoint: $5.525 → $97.50 ÷ $5.525 = 17.6x

Step 2: Choose a target multiple. The peer group trades in a wide band: Boston Scientific at 12.53x, Medtronic at 13.51x, Stryker at 16.47x, and Dexcom at 27.35x forward earnings. Abbott’s growth algorithm — 7% long-term top-line growth, high-single-digit to low-double-digit EPS growth, plus a 2.6% dividend yield — justifies a premium to Medtronic and Boston Scientific but not a Dexcom-like multiple. We use 19x as our base-case multiple, a modest premium to Stryker that reflects Abbott’s higher dividend and lower single-product risk, but slightly below the ~20x implied by the $121.08 consensus target.

Step 3: Calculate the scenarios.

Scenario	2027 EPS Assumption	Target P/E	Price Target	vs. $97.50
Bull	$6.25 (beats consensus on Volt + Libre)	21.5x	$134	+37.4%
Base	$6.07 (consensus)	19.0x	$115	+17.9%
Bear	$5.75 (nutrition/Libre disappoint)	14.0x	$80	(17.9)%

Bull: $6.25 × 21.5 = $134.38. Base: $6.07 × 19 = $115.33. Bear: $5.75 × 14 = $80.50. Rounded to the nearest dollar.

Bull case ($134). Volt reaches full U.S. availability and drives EP growth into the high teens; Libre Duo gains U.S. approval and Medicare expands Type 2 coverage; nutrition returns to growth; and management signals a portfolio simplification (for example, separating nutrition), triggering a re-rating toward the 21–22x range. This lines up with Redburn’s $127 and TD Cowen’s $135 targets.

Base case ($115). Abbott delivers its 2026 guidance and consensus 2027 EPS of $6.07, devices grow high single digits to low double digits, nutrition stabilizes, and the stock re-rates modestly to 19x as medtech sentiment normalizes.

Bear case ($80). Volt adoption stalls, another CGM quality problem or competitive pricing erodes Libre growth, nutrition keeps shrinking, and the medtech de-rating deepens to Medtronic/Boston Scientific levels (about 13–14x). In this case the stock would revisit its 52-week low of $81.97.

Probability-weighted value. Weighting 25% bull, 50% base, and 25% bear yields 0.25 × $134 + 0.50 × $115 + 0.25 × $80 = $111, or about 13.8% upside, plus a 2.6% dividend yield — a total expected return in the mid-teens over 12 months.

Cross-check: EV/Sales. Enterprise value is approximately $195.8 billion (market cap $168.71 billion + net debt $27.12 billion). On TTM sales of $46.59 billion, that is 4.2x EV/Sales. For a business with a 58% adjusted gross margin and a growing share of revenue from devices and cancer diagnostics, that multiple is reasonable, not stretched.

Comparison to analyst consensus. The Finviz consensus target is $121.08 (24.2% upside), and MarketBeat counts 3 Strong Buy, 21 Buy, and 4 Hold ratings with an average target of $119.80. Individual targets include TD Cowen at $135, Redburn at $127, Baird at $121, JPMorgan at $120, and Wells Fargo and Citigroup at $112 each.

We agree with the direction of the consensus but are slightly more conservative on the multiple. The consensus target implies roughly 20x 2027 EPS. Given that Medtronic and Boston Scientific are trading at 12.5–13.5x, we think it is prudent to assume the medtech de-rating persists for a while and to set our base case at 19x. If Q3 results on October 21 show clear Volt traction and nutrition improvement, we would be comfortable moving toward the consensus figure.

—

6. Risk Factors

Risk 1: Product quality and litigation exposure (Libre recall and NEC). Abbott’s 2026 has been shaped by legal and quality events. In December 2025, Abbott recalled about 3 million FreeStyle Libre 3 and Libre 3 Plus sensors because of incorrectly low glucose readings, with 860 serious injuries and seven deaths reported as of January 7, 2026, and plaintiffs’ firms are pursuing lawsuits. Separately, in April 2026 a Chicago jury ordered Abbott to pay $70 million in a case alleging its Similac Special Care preterm formula caused necrotizing enterocolitis (NEC), and on August 20, 2026, Abbott agreed to pay $670 million to settle roughly 2,000 NEC claims. The settlement removes a large part of the NEC overhang, but any remaining claims, appeals, or a new device quality issue could produce further charges and, more importantly, damage physician and patient trust. For a CGM business that depends on accuracy, a second major recall would be a far more serious event than the first.

Risk 2: Pulsed field ablation competition and execution. Abbott entered U.S. PFA later than its main rivals, competing against Boston Scientific’s Farapulse, Medtronic’s PFA systems, and Johnson & Johnson. Boston Scientific’s experience in 2026 — strong 24% EP growth but more share loss than expected, followed by a guidance cut and a stock price at a 52-week low — shows how quickly sentiment can turn in this market. If Volt 2.0’s full U.S. release in Q3 encounters supply constraints, clinical concerns, or slower-than-expected physician adoption, the EP growth acceleration that underpins both the Redburn upgrade and management’s second-half guidance would not materialize. Watch U.S. EP growth in the Q3 and Q4 reports carefully.

Risk 3: Acquisition integration and balance-sheet leverage. The $23 billion Exact Sciences acquisition raised net debt from $5.2 billion to $27.1 billion in six months and diluted 2026 EPS by about $0.20. Integration has gone smoothly so far, but the value of the deal depends on Cologuard sustaining mid-teens volume growth while blood-based screening tests enter the market. If Cologuard growth slows sharply, Abbott could face goodwill impairment risk on a $35.2 billion goodwill balance, and the higher debt load would limit capital returns beyond the dividend for several years. Higher-for-longer interest rates would add to the cost of refinancing the new notes over time.

Risk 4: Nutrition remains a drag. Nutrition is still 17% of revenue and declined 3.6% on a comparable basis in Q2. Management’s second-half outlook relies heavily on nutrition improving. If the WIC contract loss, consumer trade-down, or GLP-1-related shifts in adult nutrition demand keep volumes falling, overall comparable growth could land at the low end of the 6.5%–7.5% range or below.

Risk 5: Sector-wide medtech de-rating. Even if Abbott executes, the stock could stay range-bound if investors continue to compress multiples across medtech, as reflected in Medtronic and Boston Scientific trading at 12.5–13.5x forward earnings. Our bear case explicitly models this scenario.

—

7. Conclusion & Exit Plan

Investment rating: Buy.

The Abbott Redburn upgrade crystallizes a view we share: after a year of bad news — a sensor recall, an acquisition-related guidance cut, nutrition weakness, and infant-formula litigation — Abbott’s core growth engines are re-accelerating. Medical Devices grew 8.4% in Q2, Electrophysiology grew 13.4% before Volt reached full U.S. release, Cancer Diagnostics grew 13.3%, and the company raised its full-year EPS guidance. Yet the stock trades at only 16.07x consensus 2027 EPS with a 2.6% dividend yield. We see base-case value of $115 (+17.9%) and bull-case value of $134 (+37.4%), against a bear case of $80 (-17.9%).

Entry price range: $90–$100. The current $97.50 sits within this range. Below $90, the stock would trade at under 15x 2027 consensus EPS, a level we consider attractive given Abbott’s dividend record and growth profile. We would consider building a position in two tranches: half now, and half after the October 21 Q3 report confirms Volt and nutrition trends.

Exit conditions:

– Target achieved: Trim one-third of the position at the base-case target of $115; sell the remainder at the bull-case target of $134 unless 2027 EPS estimates have moved meaningfully higher.
– Fundamental break: Sell if (a) Medical Devices comparable growth falls below 6% for two consecutive quarters, (b) Abbott announces another major Libre sensor recall, or (c) management guides 2027 adjusted EPS below $5.80, which would imply the growth algorithm is broken.
– Time-based: Reassess after the Q4 2026 report in January 2027, when Abbott issues 2027 guidance, and in any case within 12 months.

Key catalysts to monitor:

1. Q3 2026 earnings on October 21 (adjusted EPS guidance $1.38–$1.46)
2. U.S. Volt 2.0 full-release adoption and EP growth rate
3. FDA decisions on Amulet 360 (potential year-end) and Libre Duo
4. Medicare coverage decisions for Type 2 CGM users
5. Any portfolio simplification announcement involving nutrition

Summary table

Item	Detail
Company	Abbott Laboratories (ABT)
Current Price	$97.50
Target Price	$115 (base); $134 (bull); $80 (bear)
Upside	17.9% (base)
Rating	Buy
Key Thesis	Device and cancer-diagnostics growth re-accelerating while the stock trades at 16x forward earnings with a 2.6% yield
Main Risk	Volt PFA execution in a crowded market and further quality or litigation events

For investors who want a diversified, dividend-growing healthcare holding with exposure to three secular growth markets — CGM, cardiac ablation, and cancer screening — Abbott at under $100 offers an attractive risk-reward balance. The October 21 report is the next test of whether the second-half acceleration is real.

—

Disclaimer

This content is general investment information provided to an indefinite/unspecified audience by a quasi-investment advisory business registered under Korea’s Financial Investment Services and Capital Markets Act, and is not personalized 1:1 investment advice tailored to any individual investor. This analysis is for informational purposes only and is not a solicitation to invest. All investment decisions and their consequences rest solely with the investor. The estimates and assumptions in this report are as of the writing date (2026-10-03) and may not materialize depending on market conditions and geopolitical variables. Financial data used reflects sources such as company filings and analyst consensus, and the scenarios and price targets represent the author’s conservative assessment. All investments carry the risk of principal loss, and past performance or analytical track record does not guarantee future results. As of the writing date, the author does not hold a position in this stock. The author’s holdings and positions may change without prior notice depending on market conditions.